Domain and Rusnano Back Marinus Pharma with $11.44M
December 21, 2012
According to a recent SEC filing, Marinus Pharmaceuticals has raised $11.44 million of an expected $21.2 million in later-stage venture funding. Marinus is “a specialty pharmaceutical company dedicated to the reformulation, development and commercialization of ganaxolone, the most advanced neurosteroid in development,” according to its website. To date, the company has raised over $70 million in total funds from Canaan Partners, Sofinnova Ventures and Foundation Medical Partners, as well as Domain Associates and Rusnano, the two investors behind Marinus’ most recent round of financing.